John Chapin

John Chapin

Company: CRISPR Therapeutics

Job title: Senior Director


John Chapin, MD is currently an executive medical director and clinical development lead on the hemoglobinopathies programs at CRISPR Therapeutics in Cambridge, MA. John has been working in gene and cell therapy drug development for four years in non-malignant hematology disorders including β-thalassemia, sickle cell disease, hemophilia, and complement-mediated diseases. John received his MD from the University of Vermont Larner College of Medicine and completed his internal medicine residency at Montefiore/Albert Einstein College of Medicine and hematology/oncology fellowship at New York Presbyterian Hospital.  John was an assistant professor of medicine at Weill Cornell Medicine-New York Presbyterian Hospital associated with the New York Comprehensive Thalassemia Center and the Weill Cornell Regional Hemophilia Center.


Panel Discussion – Discussing Challenges of Gene Editing Approaches in the Gene Therapy Space 11:45 am

Translating from pre-clinical studies into the clinic How to decide which gene editing approach is best for each indication Navigating the regulatory landscape Ensuring patients understand what treatment involves compared to current options Possible applications of gene editing technology across blood disease indicationsRead more

day: Day Two

Exploring Patient Recruitment Challenges in Sickle Cell Disease and β-Thalassemia 12:00 pm

Discussing community-specific patient recruitment challenges of sickle cell disease Highlighting β-thalassemia-specific patient dynamics and how they influence patient recruitment Prioritizing education of eligible patient groups to encourage trial participation Understanding how to optimize patient experience considering the nature of the treatmentRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.